Single-analyte assays using Elisa technology
Alzheimer’s disease (AD) is the most common form of dementia and is histologically characterized by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout the brain. The major constituents of amyloid plaques are the β-amyloid peptides consisting of 40 and 42 amino acids, which are derived from the amyloid precursor protein. Neurofibrillary tangles are made up of paired helical filaments consisting of hyperphosphorylated tau protein (phospho-tau). Tau protein, present in the brain in 6 different isoforms, is an intracellular protein that is released upon neuronal death.
Art. # 80062 (RUO - 96 Tests) - Please contact your local Fujirebio representative for the availability of this product in your country.
RUO - for research use only. Not for use in diagnostic procedures.
The INNOTEST® assay described here is a solid-phase enzyme immunoassay for the quantitative determination of phospho-tau(181P) in human cerebrospinal fluid (CSF). This assay is for research use only and not for use in diagnostic procedures.
Advantages of our assays
- Simple colorimetric immunoassays that are easily automated on microplate-processor
- Supported by many peer-reviewed scientific publications
- Less than 300 μL of CSF necessary for determination of complete biomarker profile
- Assay range consistent with biological range of values
A license regarding amyloid beta antibodies contained in this product under patents US 570349 and EP 0683234 has been obtained from Takeda Pharmaceutical Company Limited. Furthermore, a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 5,593,846A, US 5,766,846A, US 5,837,672A, US 6,284,221B1, US 6,610,493B1, US 5,441,870A, US 5,721,130A, US 5,605,811A and US 6,114,133A has been obtained from Eli Lilly and Company.
These resources are either available in free access or for users holding a Premium eServices account: